Drug news
NICE rejects Jevtana for Prostate Cancer
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance declining to recommend Jevtana (cabazitaxel) from Sanofi-Aventis for prostate cancer patients already treated with Taxotere ( docetaxel). Reasons given are the high cost of the new drug and concerns about adverse events. Sanofi is promoting Jevtana as a replacement for now generic Taxotere.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins